• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    11/14/24 5:47:31 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORIC alert in real time by email
    SC 13G/A 1 tm2427660d3_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    ORIC Pharmaceuticals, Inc. 

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share 

    (Title of Class of Securities)

     

    68622P109 

    (CUSIP Number)

     

    September 30, 2024 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   68622P109
    1.

    Names of Reporting Persons

    Nextech Crossover I SCSp

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Luxembourg

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    5,285,714 shares

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    5,285,714 shares

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,285,714 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    7.5% (2)

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1)This Schedule 13G is filed by Nextech Crossover I SCSP (“Nextech Crossover LP”), Nextech Crossover I GP S.à. r.l. (“Nextech Crossover GP”), Ian Charoub, (“Charoub”), Costas Constantinides (“Constantinides”) and Rocco Sgobbo (“Sgobbo” and, with Nextech Crossover LP, Nextech Crossover GP, Charoub and Constantinides, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The percent of class was calculated based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.

     

    2

     

     

    CUSIP No.   68622P109
    1.

    Names of Reporting Persons

    Nextech Crossover I GP S.à r.l.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Luxembourg

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    5,285,714 shares

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    5,285,714 shares

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,285,714 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    7.5% (2)

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The percent of class was calculated based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.

     

    3

     

     

    CUSIP No.   68622P109
    1.

    Names of Reporting Persons

    Ian Charoub

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Sweden

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    5,285,714 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    5,285,714 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,285,714 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    7.5% (2)

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The percent of class was calculated based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.

     

    4

     

     

    CUSIP No.   68622P109
    1.

    Names of Reporting Persons

    Costas Constantinides

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Cyprus

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    5,285,714 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    5,285,714 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,285,714 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    7.5% (2)

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The percent of class was calculated based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.

     

    5

     

     

    CUSIP No.   68622P109
    1.

    Names of Reporting Persons

    Rocco Sgobbo

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Switzerland

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    5,285,714 shares

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    5,285,714 shares

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,285,714 shares

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    7.5% (2)

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)The percent of class was calculated based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.

     

    6

     

     

    Item 1.
     
      (a)

    Name of Issuer

     

    ORIC Pharmaceuticals, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

     

    240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080

     
    Item 2.
     
      (a)

    Name of Person Filing

     

    Nextech Crossover I SCSp (“Nextech Crossover LP”)

    Nextech Crossover I GP S.à r.l. (“Nextech Crossover GP”)

    Ian Charoub (“Charoub”)

    Costas Constantinides (“Constantinides”)

    Rocco Sgobbo (“Sgobbo”)

      (b)

    Address of Principal Business Office or, if none, Residence

     

    8 rue Lou Hemmer

    L-1748 Luxembourg-Findel

    Grand-Duché de Luxembourg

      (c)

    Citizenship

     

      Name Citizenship or Place of Organization
      Nextech Crossover LP Luxembourg
      Nextech Crossover GP Luxembourg
      Charoub Sweden
      Constantinides Cyprus
      Sgobbo Switzerland

      (d)

    Title of Class of Securities

     

    Common stock, par value $0.0001 per share (“Common Stock”)

      (e)

    CUSIP Number

     

    68622P109

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

    7

     

     

    Item 4. Ownership
       
    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:

     

    Reporting Persons   Shares
    Held

    Directly
        Sole
    Voting
    Power
        Shared
    Voting
    Power (1)
        Sole
    Dispositive
    Power
        Shared
    Dispositive

    Power (1)
        Beneficial
    Ownership
        Percentage
    of Class 
    (1) (2)
     
    Nextech Crossover LP (1)     5,285,714       5,285,714       0       5,285,714       0       5,285,714       7.5 %
    Nextech Crossover GP (1)     0       5,285,714       0       5,285,714       0       5,285,714       7.5 %
    Charoub (1)     0       0       5,285,714       0       5,285,714       5,285,714       7.5 %
    Constantinides (1)     0       0       5,285,714       0       5,285,714       5,285,714       7.5 %
    Sgobbo (1)     0       0       5,285,714       0       5,285,714       5,285,714       7.5 %

     

    (1)The shares are held by Nextech Crossover LP. Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP and has sole voting and investment control over the shares owned by Nextech Crossover LP and may be deemed to own beneficially the shares held by Nextech Crossover LP. Nextech Crossover GP owns no securities of the Issuer directly. Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover GP and share voting and dispositive power over the shares held by Nextech Crossover LP, and may be deemed to own beneficially the shares held by Nextech Crossover LP. Charoub, Constantinides and Sgobbo own no securities of the Issuer directly.
    (2)The percent of class was calculated based on 70,542,476 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    8

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Nextech Crossover I SCSp  
         
    By: Nextech Crossover I GP S.à r.l.  
    its General Partner  
         
    By: /s/ Ian Charoub  
      Name: Ian Charoub  
      Title: Manager  
         
    By: /s/ Costas Constantinides  
      Name: Costas Constantinides  
      Title: Manager  
         
    Nextech Crossover I GP S.à r.l.  
         
    By: /s/ Ian Charoub  
        Name: Ian Charoub  
        Title: Manager  
         
    By: /s/ Costas Constantinides  
        Name: Costas Constantinides  
        Title: Manager  
         
    /s/ Ian Charoub  
    Ian Charoub  
         
    /s/ Costas Constantinides  
    Costas Constantinides  
         
    /s/ Rocco Sgobbo  
    Rocco Sgobbo  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    9

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    10

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of ORIC Pharmaceuticals, Inc. is filed on behalf of each of us.

     

    Dated: November 14, 2024

     

    Nextech Crossover I SCSp  
         
    By: Nextech Crossover I GP S.à r.l.  
    its General Partner  
         
    By: /s/ Ian Charoub  
      Name: Ian Charoub  
      Title: Manager  
         
    By: /s/ Costas Constantinides  
      Name: Costas Constantinides  
      Title: Manager  
         
    Nextech Crossover I GP S.à r.l.  
         
    By: /s/ Ian Charoub  
        Name: Ian Charoub  
        Title: Manager  
         
    By: /s/ Costas Constantinides  
        Name: Costas Constantinides  
        Title: Manager  
         
    /s/ Ian Charoub  
    Ian Charoub  
         
    /s/ Costas Constantinides  
    Costas Constantinides  
         
    /s/ Rocco Sgobbo  
    Rocco Sgobbo  

     

     

     

    Get the next $ORIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORIC

    DatePrice TargetRatingAnalyst
    10/31/2024$20.00Overweight
    Wells Fargo
    9/6/2024$20.00Buy
    Stifel
    2/23/2024Overweight
    Cantor Fitzgerald
    9/22/2023$8.00Outperform
    Wedbush
    3/23/2023$16.00Neutral → Buy
    H.C. Wainwright
    3/21/2023$15.00Neutral → Buy
    Guggenheim
    3/16/2023$14.00Perform → Outperform
    Oppenheimer
    7/18/2022Perform
    Oppenheimer
    More analyst ratings

    $ORIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

      Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of regi

      5/5/25 4:05:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO Calif. and SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2025 (the "Grant Date"), ORIC granted a total of 32,400 non-qualified stock options and 5,200 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock opti

      5/2/25 4:30:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of a poster at the 2025 American Association for Cancer Research (AACR) Annual Meeting, highlighting preclinical data on ORIC-944, a potent, highly selective, orally bioavailable allosteric inhibitor of PRC2, which demonstrated synergistic activity and improved progression-free survival (PFS) when combined with androgen receptor pathway inhibitors (ARPIs) in models of prostate cancer. "We are excited by the potential of

      4/28/25 4:30:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kunkel Lori Anne exercised 48,166 shares at a strike of $4.85, increasing direct ownership by 235% to 68,666 units (SEC Form 4)

      4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

      3/4/25 5:27:04 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director You Angie

      4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

      1/6/25 4:47:57 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kunkel Lori Anne

      4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

      1/6/25 4:46:39 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on ORIC Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      10/31/24 6:33:23 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on ORIC Pharmaceuticals with a new price target

      Stifel initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $20.00

      9/6/24 7:48:52 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals

      Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals with a rating of Overweight

      2/23/24 7:13:54 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

      SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      11/14/24 5:54:12 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

      SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      11/14/24 5:47:31 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

      SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      11/14/24 5:14:58 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Leadership Updates

    Live Leadership Updates

    See more
    • ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

      Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected

      2/18/25 4:05:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

      Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO and SAN DIEGO, J

      1/13/25 8:05:00 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

      Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resis

      11/12/24 4:05:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

      SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      5/15/25 5:47:21 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

      SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

      5/15/25 4:35:08 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Oric Pharmaceuticals Inc.

      10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

      5/5/25 4:20:18 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORIC
    Financials

    Live finance-specific insights

    See more
    • Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

      Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11

      12/11/23 12:00:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

      CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion

      10/21/23 7:30:00 AM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

      SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. In conjunction with the ESMO presentations, OR

      10/17/23 4:30:00 PM ET
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care